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Abstract
 
Hepatitis B virus (HBV) is a noncytopathic virus, and the recognition of infected hepatocytes
by HBV-specific CD8 cells has been assumed to be the central mechanism causing both liver
damage and virus control. To understand the role of cytotoxic T cells in the pathogenesis of
HBV infection, we used functional assays that require T cell expansion in vitro and human his-
tocompatibility leukocyte antigen (HLA)-peptide tetramers that allow direct ex vivo quantifi-
cation of circulating and liver-infiltrating HBV-specific CD8 cells. Two groups of patients with
persistent HBV infection were studied: one without liver inflammation and HBV replication,
the other with liver inflammation and a high level of HBV replication. Contrary to expecta-
tion, a high frequency of intrahepatic HBV-specific CD8 cells was found in the absence of he-
patic immunopathology. In contrast, virus-specific T cells were more diluted among liver infil-
trates in viremic patients, but their absolute number was similar because of the massive cellular
infiltration. Furthermore, inhibition of HBV replication was associated with the presence of a
circulating reservoir of CD8
 
1
 
 cells able to expand after specific virus recognition that was not
detectable in highly viremic patients with liver inflammation.
These results show that in the presence of an effective HBV-specific CD8 response, inhibi-
tion of virus replication can be independent of liver damage. When the HBV-specific CD8 re-
sponse is unable to control virus replication, it may contribute to liver pathology not only di-
rectly but by causing the recruitment of nonvirus-specific T cells.
Key words: hepatitis • tetramers • antiviral cytotoxic T lymphocytes • cell migration • 
immunopathology 
 
Introduction
 
300 million people worldwide have a persistent infection
with hepatitis B virus (HBV)
 
1
 
 and are at risk of developing
chronic liver inflammation leading to cirrhosis and hepato-
cellular carcinoma (1). Although the pathogenesis of
chronic liver disease is not well understood, there is a con-
sensus that liver damage is immune mediated. Since the vi-
rus is preferentially hepatotropic and not cytopathic, it has
been assumed that the recognition of HBV-infected hepa-
tocytes by Ag-specific HLA class I–restricted CTLs is caus-
ing the liver damage (2). This hypothesis is supported by a
transgenic mouse model of HBV infection (3), in which
liver damage occurs after transfer of virus-specific CD8
cells. In human HBV infection, studies have been ham-
pered by the inability of HBV to infect cells in vitro and by
the difficulty of studying the intrahepatic compartment.
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Abbreviations used in this paper:
 
 ALT, alanine transaminase; HBc, HBV
core; HBe, HBV e; HBs, HBV surface; HBV, hepatitis B virus; HCV,
hepatitis C virus; Tc 18–27, core 18–27 HLA-A2 tetrameric complex;
Te 335–343, envelope 335–343 HLA-A2 tetrameric complex; Tp 575–
583, polymerase 575–583 HLA-A2 tetrameric complex. 
1270
 
Role of HBV-specific CD8 Cells during Persistent Infection
 
For these reasons, knowledge of the HBV-specific CTL re-
sponse has been mostly restricted to the circulating com-
partment, relying on in vitro cell culture after peptide stim-
ulation and confined to HLA-A2
 
1
 
 patients (for a review,
see reference 4).
 
 
 
Overall, these data have shown a better
correlation between the virus-specific CD8 response and
protection, rather than liver damage. Indeed, patients with
acute HBV infection, who clear circulating virus, present a
strong and multispecific CTL response that persists in the
circulation without further liver damage (5–8). In contrast,
this response is barely detectable in the circulation of
chronic patients despite clinical and histological signs of
liver damage (9), except after resolution when viral replica-
tion is controlled (10).
The low level of virus-specific CD8 cells in the circula-
tion of chronic patients has been partially reconciled with a
model of liver damage mediated by HBV-specific cyto-
toxic CD8 cells by the assumption that HBV-specific CTLs
are preferentially sequestered in the liver, where they cause
persistent hepatic damage without complete virus eradica-
tion (2). HBV-specific CD4 and CD8 cells have been
shown to infiltrate the liver (11, 12), but it is not known
whether they represent the majority of intrahepatic cells or
whether their number is proportional to the extent of liver
damage. In addition, reports that have correlated the num-
ber of intrahepatic T cells with hepatocyte damage have
not investigated the specificity of these cells (13–18). In this
study, we examined the relationships among the circulating
and intrahepatic HBV-specific CD8 response, liver dam-
age, and virus replication.
HBV-specific CD8 cells were visualized directly in differ-
ent T cell populations using HLA–peptide tetrameric com-
plexes. The tetramer consists of four biotinylated HLA class I
molecules, each folded with a nominal peptide and multim-
erized by the addition of streptavidin. This multimeric HLA
class I–peptide complex has a high avidity for T cells display-
ing the appropriate T cell receptor. Binding to specific cells
is detectable by flow cytometry if a fluorochrome-labeled
streptavidin reagent is used (19).
 
 
 
Tetramer staining has facili-
tated the dissection of cell-mediated immunity in several vi-
ral infections (20–24), and we have recently reported the use
of HBV-specific tetramers during acute HBV infection (25).
This new approach allows direct quantification of virus-spe-
cific cells in lymphocytes of peripheral blood and, impor-
tantly, in intrahepatic lymphocyte infiltration.
Since the yield of T cells purified from diagnostic biop-
sies is very low (typically 0.5–5 
 
3 
 
10
 
5
 
 cells), information
about specific intrahepatic T cells has so far only been pos-
sible after extensive in vitro stimulation, which may alter
the detection of the immune events taking place in vivo.
To overcome this limitation, tetramers specific for known
HLA-A2–restricted CTL epitopes were used to quantify
the frequency of HBV-specific CD8 cells directly ex vivo
from the circulation and liver of chronically infected HBV
patients. This approach allowed us to compare the fre-
quency, compartmentalization, and functional responsive-
ness of HBV-specific CD8 cells in patients differing in their
extent of liver damage and viral control.
 
Materials and Methods
 
Patients and Controls.
 
A total of 49 (36 men and 13 women)
patients with chronic HBV were included in this study. 33 of
them were HLA-A2
 
1
 
. The remaining 16 were HLA-A2
 
2
 
 and
served as a control group. An additional control group comprised
five HLA-A2
 
1
 
 healthy subjects without evidence of exposure to
HBV (i.e., negative for HBV surface [HBs]Ag and anti-HBV
core [HBc] Abs). All patients with chronic HBV infection were
HBsAg and anti-HBc positive and were negative for Abs to hep-
atitis C virus (HCV), delta virus, and to HIV-1 and -2 (except
patient 20, who was anti–HIV-1
 
1
 
, with a normal CD4 count).
Patients on current or recent (last 6 mo) antiviral therapy were
excluded from the study. HLA-A2
 
1
 
 patients were divided in two
groups according to their serum HBV DNA level and alanine
transaminase (ALT) level at the time of investigation (see Table
I). Analysis of demographic characteristics (age, sex, source of in-
fection) showed no significant differences between the two
groups (data not shown). Patients with HBV DNA level 
 
,
 
2 pg/
ml and ALT 
 
,
 
35 U/liter were all HBV e (HBe)Ag
 
2
 
 and anti-
HBe
 
1
 
, had no documented evidence of recent seroconversion
(HBeAg
 
1
 
 to anti-HBe Ab) or flare, and had been tested for ALT
normality on at least two occasions in the month before tetramer
analysis.
 
 
 
Patients with HBV DNA level 
 
.
 
800 pg/ml and ALT
 
.
 
70 U/liter were all HBeAg
 
1
 
 and anti-HBe
 
2
 
. 10 patients under-
went percutaneous needle liver biopsy as part of their diagnostic
evaluation (see Table I). The biopsies were divided in two parts:
one for histological examination, the other for research. The his-
tological diagnosis of the patients with HBV DNA level 
 
,
 
2 pg/
ml and ALT 
 
,
 
35 U/liter was “normal liver” (patients 9, 15, and
17) or liver with minimal evidence of liver inflammation (patients
16 and 18). The histological diagnosis of the patients with HBV
DNA level 
 
.
 
800 pg/ml and ALT 
 
.
 
70 U/liter was chronic ac-
tive hepatitis, with massive portal infiltration of mononuclear cells
(patients 19, 20, 32, and 33). One patient (patient 31) also
showed extensive parenchymal infiltration of mononuclear cells.
 
Virological Assessment.
 
HBsAg, anti-HBs, total and IgM anti-
HBc, HBeAg, anti-HBe, anti-delta, anti-HCV, anti–HIV-1, and
anti–HIV-2 were determined by commercial enzyme immuno-
assay kits (Abbot Laboratories; Ortho Diagnostic System; and
Sanofi Diagnostic Pasteur). HBV DNA level was quantified by
commercial hybridization assay (Digene).
 
Tissue Typing.
 
Screening for the HLA-A2 haplotype was per-
formed by staining PBMCs with an anti–HLA-A2 Ab (Incstar)
followed by an FITC-conjugated goat anti–mouse IgG second
layer and flow cytometric analysis. Patients were subsequently
confirmed to have the HLA-A2.01 allele by PCR DNA typing.
 
Synthesis of HLA-A2–Peptide Tetrameric Complexes.
 
Soluble
HLA-A2–peptide tetramers were produced as described previ-
ously (26). In brief, recombinant class I (HLA-A2) heavy chains
and 
 
b
 
2-microglobulin were produced in 
 
Escherichia coli
 
 cells trans-
formed with the relevant expression vectors. Only the extracellu-
lar domain of class I heavy chain was expressed, after modification
by replacement of the COOH-terminal domain with a substrate
sequence for BirA biotinylation. Complexes were folded in vitro
using 30 mg of HLA-A2 heavy chain protein, 25 mg of 
 
b
 
2-micro-
globulin, and 10 mg of synthetic peptide. Sequences of HBV
(genotype D) peptides used were FLPSDFFPSV (core 18–27),
FLLSLGIHL (polymerase 575–583), and WLSLLVPFV (enve-
lope 335–343). The HLA-A2–peptide complexes were biotiny-
lated using purified BirA enzyme at a concentration of 5 
 
m
 
g/ml,
0.5 mM biotin, and 5 mM ATP. The reaction was incubated at
room temperature for 16 h. Biotinylated HLA-A2–peptide com-
plexes were recovered by fast protein liquid chromatography pu- 
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rification (using buffer containing 20 mM Tris, pH 8.0, and 50
mM NaCl) and ion exchange chromatography (0–0.5 M NaCl
gradient). Tetramers were generated by mixing biotinylated pro-
tein complex with streptavidin-PE at a molar ratio of 4:1.
 
Synthetic Peptides.
 
Peptides corresponding to the sequence of
core 18–27, envelope 335–343, and polymerase 575–583 region
of HBV genotype D were purchased from Chiron Mimotopes.
 
HLA-A2 Tetramer and Ab Staining.
 
PBMCs were isolated
from heparinized blood samples by density gradient centrifuga-
tion on Ficoll-Hypaque. Mononuclear cells were purified from
biopsies according to previous methods (27). In brief, excess liver
tissue not needed for diagnostic purposes was extensively washed
in RPMI and then digested with collagenase (1 mg/ml; Sigma
Chemical Co.) and DNase (25 
 
m
 
g/ml; Sigma Chemical Co.) for
1 h at 37
 
8
 
C. The cell suspension was washed twice, and mono-
nuclear cells were recovered by centrifugation over a Ficoll-
Hypaque density gradient.
0.5–1 
 
3
 
 10
 
6
 
 PBMCs or variable numbers of liver-infiltrating
mononuclear cells (always 
 
.
 
0.05 
 
3
 
 10
 
6
 
) were incubated for 30
min at 37
 
8
 
C with 1 
 
m
 
g of PE-labeled tetrameric complex in
RPMI 1640, 10% FCS in round-bottomed polystyrene tubes
(Becton Dickinson). Cells were washed in PBS and then incu-
bated at 4
 
8
 
C for 30 min with saturating concentrations of directly
conjugated anti-CD8–Cychrome (PE-Cy5) mAb (Sigma Chemi-
cal Co.) and one of a panel of FITC-conjugated Abs. For pheno-
typing experiments, these consisted of anti–HLA-DR, anti-
CD45RA, anti-CD38, and anti-CD62L (PharMingen). Cells
were washed twice and then analyzed immediately on a Becton
Dickinson FACS
 
® 
 
using CELLQuest™ software. For analysis of
circulating tetramer
 
1
 
 cells, 
 
z
 
0.4 
 
3
 
 10
 
6
 
 cells were acquired
within the live gate
 
 
 
to ensure that at least 0.05 
 
3
 
 10
 
6
 
 CD8 cells
were available for analysis. For analysis of liver-infiltrating
tetramer
 
1
 
 cells, all the cells available from a given biopsy were
processed and acquired, to analyze at least 10
 
4
 
 CD8 cells within
the live gate.
 
Production of T Cell Lines.
 
T cell lines were produced as de-
scribed previously (6). In brief, PBMCs were resuspended at a
concentration of 3 
 
3
 
 10
 
6
 
/ml in RPMI 1640, 10% FCS. Cells
were stimulated with 1 
 
m
 
M of core 18–27 peptide in a 96-well
plate. Recombinant IL-2 (50 IU/ml) was added on day 4 of cul-
ture, and cells were analyzed after a total of 10–12 d of culture.
 
Chromium-release Assays.
 
T cell lines were tested for cytotoxic
activity using HLA-A2–matched EBV-B cells as targets, labeled
with 100 
 
m
 
Ci 
 
51
 
Cr (Na
 
51
 
CrO
 
4
 
; Amersham International plc) for
1 h at 37
 
8
 
C. After washing, targets were diluted in RPMI 1640,
10% FCS and pulsed or unpulsed for 1 h with 1 
 
m
 
M of the ap-
propriate peptide before being added to effector T cell lines at the
indicated E/T ratios in 96-well round-bottomed plates. Chro-
mium release was measured in the supernatant after 5 h of incu-
bation at 37
 
8
 
C, and percent specific lysis was calculated as de-
scribed (9).
 
Intracellular IFN-
 
g
 
 Staining.
 
Core 18–27-specific T cell lines
were incubated for 4 h at 37
 
8
 
C at 1 
 
3
 
 10
 
6
 
 cells/ml in RPMI
1640, 10% FCS with PMA (5 ng/ml) and ionomycin (1 
 
m
 
M) in
the presence of Brefeldin A (10 
 
m
 
g/ml; Sigma Chemical Co.).
Cells were washed and surface stained with tetramer as above
(tetramer staining was also performed before stimulation, giving
equivalent results). After a further wash, cells were subjected to
intracellular staining using Permeafix (Ortho Diagnostic Systems)
to permeabilize and fix cells according to the manufacturer’s in-
structions, followed by staining with FITC-conjugated anti–IFN-
 
g
 
Ab and its isotope-matched control (PharMingen). Cells were
washed twice and analyzed by flow cytometry. For the peptide
 
stimulation experiment, fresh PBMCs were stimulated with core
18–27 peptide (1 
 
m
 
M) for 6 h, with addition of Brefeldin A (10
 
m
 
g/ml) after the first 1 h of this incubation. Surface staining with
tetramer, permeabilization, and intracellular staining were then
carried out as above.
 
PCR and HBV DNA Sequencing.
 
DNA was extracted from
serum samples taken at the time of liver biopsy using QIAmp
DNA Blood mini kit (QIAGEN). The HBV DNA was amplified
with primers specific for the HBV core gene, as described previ-
ously (28). The amplicons were purified and the precore/core
region was sequenced directly using an automated sequencer
(model ABI 377; Applied Biosystems).
 
Immunohistochemistry of the Liver.
 
The distribution of CD8
 
1
 
 T
lymphocytes in the liver was visualized by immunostaining in
formalin-fixed, paraffin-embedded liver specimens. The liver sec-
tions were first microwaved in a citrate buffer (pH 6.0) for Ag re-
trieval, followed by incubation with an mAb to human CD8
molecule (clone C8/144B; Dako). The detection was with a sen-
sitive immunoperoxidase kit (EnVision HRP system; Dako) with
diaminobenzidine as a substrate, and the sections were counter-
stained with hematoxylin. The number of CD8
 
1
 
 T lymphocytes
in the portal tracts and the intralobular areas was scored in equiv-
alent fields (
 
3
 
400).
Hepatic expression of HBcAg was detected by immunostain-
ing of formalin-fixed, paraffin-embedded liver specimens, as de-
scribed previously (29). Polyclonal, rabbit anti-HBc (Dako) and
an immunoalkaline phosphatase kit (En Vision System AP; Dako)
were used in these experiments.
 
Results
 
Frequency of Circulating HBV-specific CD8 Cells.
 
HBV-
infected patients were selected for study on the basis of the
expression of the HLA-A2 allele, and were grouped ac-
cording to serum levels of the liver enzyme ALT (as a mea-
sure of hepatic inflammation) and HBV DNA. The first
group was composed of 10 HLA-A2
 
1
 
 (A2
 
1
 
) patients with
chronic HBV infection who were negative for HBeAg,
and whose serum contained normal levels of ALT and 
 
,
 
2
pg/ml HBV DNA (hereafter indicated as HBV-ALT
 
¯
 
).
The second group comprised nine HLA-A2
 
1
 
 patients with
chronic HBV infection (HBeAg
 
1) with .800 pg/ml HBV
DNA and with raised serum ALT (hereafter HBV-ALT­)
(Table I). Six HLA-A22 (A22) patients with chronic HBV
infection and six A21 non–HBV-infected subjects were
also tested as negative controls.
PBMCs from patients and controls were double stained
directly ex vivo with anti-CD8 mAbs, and with HLA-A2
tetrameric complexes able to visualize CD8 cells specific
for core 18–27 (Tc 18–27), polymerase 575–583 (Tp 575–
583), and envelope 335–343 (Te 335–343) (25). The num-
ber of tetramer-binding cells was different in the two
groups of chronic HBV patients. In 9 out of 10 HBV-
ALT¯ patients, the frequency of tetramer1 cells exceeded
the level of 0.02% of circulating CD81 representing the
maximum staining observed in the controls (Table I, top,
and Fig. 1). The core 18–27-specific CD8 cells were the
numerically dominant population of tetramer1 cells in six
patients, reaching a frequency of 0.18% of circulating
CD81 cells in two patients. Polymerase tetramer1 cells1272 Role of HBV-specific CD8 Cells during Persistent Infection
were numerically dominant in three patients, while five out
of nine patients had circulating CD8 cells specific for more
than one epitope. In contrast, the ex vivo analysis of the
frequency of tetramer1 cells in HBV-ALT­ patients only
showed numbers of tetramer1 cells above the control level
in two patients (Table I, bottom, and Fig. 1).
The difference in tetramer staining between the two
groups of A21 chronic HBV patients persisted when the
Table I. HLA-A21 Patient Data
Patients HBV ALT
No. of tetramer1 cells
Sequence core
18–27
Expansion
after stim.
Liver
biopsy Tc* Tp‡ Te§
pg/ml U/liter 5 3 104 CD8
HBV-ALT¯
1 ,2 24 1 12 6 Wt Neg No
2 ,2 25 4 24 16 Wt Neg No
3 ,2 35 0 5 5 ND Neg No
4 ,2 18 5 40 4 Wt Pos No
5 ,2 17 14 8 14 ND Pos No
6 ,2 34 17 1 16 Wt Pos No
7 ,2 23 30 5 5 Wt Pos No
8 ,2 22 50 1 7 21T/24Y Pos No
9 ,2 25 90 16 31 N ampl Pos Yes
10 ,2 20 91 15 5 Wt Pos No
11 ,2 29 8 ND ND N ampl Neg No
12 ,2 19 8 ND ND ND Pos No
13 ,2 21 16 ND ND ND Pos No
14 ,2 26 23 ND ND N ampl Pos No
15 ,2 26 23 ND ND Wt Pos Yes
16 ,2 34 10 ND ND Wt ND Yes
17 ,2 30 9 ND ND Wt ND Yes
18 ,2 28 10 ND ND Wt ND Yes
HBV-ALT­
19 1,221 70 0 8 4 Wt Neg Yes
20 .2,000 70 4 14 4 Wt Neg Yes
21 .2,000 137 10 10 0 Wt ND No
22 .2,000 108 2 10 10 ND ND No
23 .2,000 234 2 10 10 ND ND No
24 835 282 4 8 0 Wt Neg No
25 .2,000 200 5 1 1 ND Neg No
26 .2,000 92 13 8 8 I27 Pos No
27 .2,000 318 2 2 4 Wt ND No
28 .2,000 85 5 ND ND ND Neg No
29 .2,000 90 5 ND ND ND Neg No
30 .2,000 211 11 ND ND Wt Neg No
31 .2,000 465 15 ND ND Wt Neg Yes
32 .2,000 75 4 ND ND Wt ND Yes
33 .2,000 60 6 ND ND I27 Neg Yes
HBV-ALT¯ patients: HBsAg1, anti-HBc1, HBeAg2, anti-HBe1; HBV-ALT­ patients: HBsAg1, anti-HBc1, HBeAg1, anti-HBe2. ND, not done;
N ampl, HBV sequence not amplified.
*Tc 18–27 CD8 cells.
‡Tp 575–583 CD8 cells.
§Te 335–343 CD8 cells.1273 Maini et al.
overall level of tetramer staining with all three tetramers
was calculated. The median level of tetramer1 cells was 54/
50,000 CD8 cells in HBV-ALT¯ patients compared with
17/50,000 CD8 cells in HBV-ALT­ patients (Fig. 1 c).
Frequency of Liver-infiltrating HBV-specific CD8 Cells.
Circulating HBV-specific CD8 cells may not accurately re-
flect the number of such cells sequestered in the liver.
Thus, the HBV-ALT­ patients may have lower circulating
frequencies of HBV-specific CD8 cells as a result of their
preferential compartmentalization within the liver. T cells
purified from the livers of 20 HBV chronic patients (10
A21, 10 A22) were analyzed for the presence of Tc 18–271
CD8 cells.
The frequency of Tc 18–271 CD8 cells among intrahe-
patic T cells purified from biopsies performed in A22 con-
trol patients (4 HBV-ALT¯, 6 HBV-ALT­) was always
,0.01% (data not shown). Tc 18–271 CD8 cells were de-
tectable at a higher frequency in the liver than the circula-
tion in 8 out of 10 A21 HBV patients, consistent with pref-
erential hepatic sequestration occurring in both groups of
patients (Fig. 2). However, the proportion of Tc 18–271
CD8 cells among the intrahepatic cellular infiltrate did dif-
fer between the two groups. Higher frequencies of Tc 18–
271 CD8 cells were observed in the HBV-ALT¯ group, in
whom as many as 1 in 11 (patient 16) or 1 in 25 (patients 9
and 15) CD8 cells were specific for this single epitope (Fig.
2 b). In the HBV-ALT­ patients, the highest frequency
seen was 1 in 120 (patient 19), and in 2 patients there were
no Tc 18–271 CD8 cells detectable either in the periphery
or in the liver (Fig. 2 b).
The finding of high frequencies of Tc 18–271 CD8 cells
in the absence of biochemical evidence of hepatocyte lysis
prompted us to examine whether recognition of the HBV
core 18–27 sequence was still possible in these patients. Se-
Figure 1. Quantification of
tetramer1 CD8 cells in the cir-
culation. (a) PBMCs from the
two groups of A21, HBV-infected
patients were stained with HBV
tetramers (Tc 18–27, Tp 575–
583, Te 335–343) and anti-CD8
mAb immediately after isolation.
The frequency of tetramer1
CD8 cells was calculated out of
50,000 CD8 cells analyzed. Re-
sults obtained in control patients
(A22 patients chronically in-
fected by HBV and A21 HBV-
uninfected subjects) are also
shown. (b) FACScan™ dot plots
of PBMCs stained with anti-
CD8 mAb and the indicated
HBV tetramers. The numbers in
the upper right quadrants indi-
cate the percent of tetramer1
cells out of total CD8 cells, cal-
culated with CELLQuest™ soft-
ware. (c) The total frequency of
Tc 18–27, Tp 575–583, and Te
335–343 positive cells out of
50,000 CD8 cells was calculated.
Results for the two groups of
patients are presented. The sum
of the frequency of tetramer1
cells for Tc 18–27, Tp 575–583,
and Te 335–343 was signifi-
cantly higher in the HBV-ALT¯
group (P , 0.01, Mann Whit-
ney U test).1274 Role of HBV-specific CD8 Cells during Persistent Infection
quencing of the HBV genome across the core 18–27
epitope did not reveal any mutations that could abrogate T
cell recognition (Table I, top). Furthermore, ongoing active
recognition of virus-infected cells was supported by pheno-
typic analysis of intrahepatic T cells in patient 16, where the
high numbers of intrahepatic Tc 18–27 CD81 cells allowed
analysis of their activation state. The great majority (z90%)
of these lymphocytes had the phenotype of recently acti-
vated cells with high levels of HLA-DR expression (Fig. 3).
Strikingly few of the remaining CD8 cells in the liver had
this activated phenotype, making it unlikely that bystander
cytokine production was the cause of their activation.
Quantification of Liver-infiltrating Tc 18–271 CD8 Cells.
We then estimated the total numbers of Ag-specific CD8
cells in the livers of patients with different clinical presenta-
tions. Different frequencies of Tc 18–271 CD8 cells could
merely reflect differing degrees of dilution in tetramer2
CD8 cells, rather than a difference in the absolute number
of HBV-specific CD81 cells.
In line with this possibility, the yield of mononuclear
cells obtained from liver biopsies was generally higher in
patients with evidence of liver disease than in those with-
out (data not shown). However, to better quantify the
number of liver-infiltrating tetramer1 cells, an immunohis-
tological comparison of the total CD8 infiltration in liver
sections was performed. These numbers were then corre-
lated with the frequency of Tc 18–271 CD8 cells obtained
in purified infiltrates. As expected, in patients with raised
liver enzymes and histological evidence of “active hepati-
tis,” a large number of CD8 cells was present in the portal
areas with some spreading into the intralobular area. By
contrast, subjects with normal liver enzymes had relatively
low numbers of infiltrating CD8 cells preferentially local-
ized within the lobules among the hepatocytes (Fig. 4 a).
Combining these findings with the frequencies of Tc 18–
271 CD8 cells found in the lymphomononuclear cells ob-
tained from the liver of the same patients, we could esti-
mate the absolute number of intrahepatic Tc 18–271 CD8
cells. As illustrated in Fig. 4 a for patients 9 and 19, this cal-
culation suggests that the frequency comparisons were mis-
leading and that the total number of liver-infiltrating Tc
18–271 CD8 cells may not differ between patients with or
Figure 2. Preferential sequestration of Tc 18–271 CD8 cells in the liver compartment. (a) Vi-
sualization of liver-infiltrating and circulating core 18–27-specific CD81 cells by tetramer stain-
ing. Dot plots show live gated cells obtained from liver or blood of the indicated patients. a
shows representative FACS® plots from two patients from each group, as indicated. Because of
the differing yields of liver-infiltrating cells, total numbers of gated cells varied but were always
.104 CD8 cells. Numbers in the upper right quadrants indicate the percentage of Tc18–27
CD81 cells within the total CD8 population. (b) Frequencies of liver and circulating Tc 18–271
CD8 cells assessed by flow cytometric analysis as illustrated in a are shown. Bars represent the
percentage of Tc 18–271 CD8 cells out of total CD8 cells. The numbers on top of the bars rep-
resent the ratio of Tc 18–271 CD8 to total CD81 cells.
Figure 3. Phenotypic analysis of liver-infiltrating Tc 18–271 CD8 cells.
Intrahepatic Tc 18–271 CD8 cells of patient 16 were analyzed by three-
color flow cytometry using the PE-conjugated Tc 18–27, cychrome-
conjugated anti-CD8, and the FITC-conjugated anti–HLA-DR. The
number in the upper right quadrant of the first dot plot indicates the per-
centage of Tc 18–27 CD81 within the total CD8 population. The grid in
the second dot plot shows the percentage of CD81 cells in each quadrant.1275 Maini et al.
without liver damage. Patients 15 and 32 showed similar
results (Table II).
Immunostaining of liver sections for HBcAg showed, as
expected, that HBcAg was undetectable in patients with
successful control of HBV replication (patients 9 and 15),
whereas patients with high levels of serum HBV DNA (pa-
tients 19 and 32) had HBcAg expression in .30% of hepa-
tocytes (not shown).
Therefore, these data showed that similar numbers of in-
trahepatic core 18–27-specific CD8 cells can be associated
with different clinical outcomes. Patients with good viral
control have a relative paucity of CD8 infiltrate composed
of a high proportion of Tc 18–271 CD8 cells. By contrast,
the absence of effective viral control is associated with a
much greater infiltration of CD8 cells, in which Tc 18–
271 CD8 cells appear more diluted.
Core 18–27-specific CD8 Cell Responsiveness. Mathe-
matical models of the dynamics of the immune response
during persistent infections have shown that there need
not be any difference in the number of virus-specific CD8
cells between individuals despite varying abilities to con-
trol the virus (30). The principal variable determining viral
control has been suggested to be the ability of virus-spe-
cific CD8 cells to clonally expand and exert their antiviral
effector functions. Therefore, we investigated the capacity
of circulating core 18–27-specific CD8 cells to expand af-
ter exposure to viral Ag and to exhibit antiviral activity.
PBMCs from 25 A21 and 6 A22 HBV carriers were
stimulated in vitro with core 18–27 synthetic peptide. Af-
ter 10 d of culture, expansion of core 18–27 CD8 cells was
quantified by staining short-term T cell lines with the ap-
propriate tetramer. No expansion of core 18–27-specific
CD8 cells was detectable in 6 A22 patients with chronic
HBV infection (data not shown). 11 out of 15 of the
HBV-ALT¯ but only 1 out of 10 HBV-ALT­ patients
demonstrated a vigorous expansion of core 18–27-specific
CD8 cells (Fig. 5). The expanded cells from patients 7, 10,
and 14 were capable of specific lysis and IFN-g production
(Fig. 6 a) when tested in vitro, suggesting that these cells
should be able to exert antiviral function after virus chal-
lenge in vivo. In addition, the high circulating frequency
of Tc 18–271 CD8 cells present in patient 10 allowed us to
Figure 4. Analysis of liver-infiltrating CD8 cells. Liver biopsies from patient 9 (HBV DNA ,2 pg/ml, ALT ,35 U/liter) and patient 19 (HBV DNA
1221 pg/ml, ALT 70 U/liter) were stained with anti-CD8 mAbs. The distribution of CD81 T lymphocytes in the liver was visualized by immunostain-
ing in formalin-fixed, paraffin-embedded liver specimens. The number of CD81 T lymphocytes in the portal tracts and intralobular areas was scored in
equivalent histological fields (original magnification: 3400). To estimate the numbers of Tc 18–271 cells present in each field, the number of CD8 cells
was multiplied by the frequency of Tc 18–271 cells obtained from CD8 cells purified from the same biopsy.
Table II. Estimation of Tc 18–271 CD8 Cells Present in 
Equivalent Liver Sections
Patients
HBV-ALT
level
CD8
cells*
Percent
intrahepatic
Tc 18–271
CD8 cells
No. of 
Tc 18–271
CD8 cells‡
19 HBV-ALT­ 138 0.8 1.1
32 HBV-ALT­ 188 0.23 0.6
9 HBV-ALT¯ 40 4 1.6
15 HBV-ALT¯ 25 4 1
*The number of CD8 T lymphocytes was scored in equivalent histo-
logical fields (3400).
‡Calculated by multiplying the number of CD8 cells as above by the
frequency of Tc 18–271 measured by tetramer staining of purified in-
trahepatic CD8 cells from the same biopsy.1276 Role of HBV-specific CD8 Cells during Persistent Infection
demonstrate that core 18–27-specific CD8 cells produced
IFN-g when stimulated with the specific peptide directly
ex vivo (Fig. 6 b).
Interestingly, the only HBV-ALT­ patient with a popu-
lation of HBV-specific CD8 cells capable of expansion
(Fig. 5) was found to harbor a virus with Ile at position 27
(Table I). Position 27 is one of the two major anchor resi-
dues in the core 18–27 epitope, and Ile at position 27 is a
naturally occurring variant known to reduce the binding
affinity of the peptide to HLA-A2 (9, 31). Thus, the I27
sequence will not be efficiently presented on the surface of
HBV-infected cells. Therefore, the core 18–27-specific
CD8 cells that were expanded in vitro by stimulation with
the prototype 18–27 sequence (presumably primed by pre-
vious exposure to the wild-type virus [32]) would not con-
trol this patient’s infecting virus efficiently.
The relatively high frequency of circulating Tc 18–271
CD8 cells in patients 7 and 10 (HBV-ALT¯) allowed di-
rect analysis of their phenotype by three-color flow cy-
tometry. The Tc 18–271 CD8 cells had low expression of
T cell activation markers (HLA-DR, CD38), and were
mainly negative for L-selectin (CD62L, the lymphocyte
homing receptor) and for CD45RA (the high molecular
weight isoform of CD45 conventionally associated with a
naive phenotype). This combined phenotype is character-
istic of nonactivated Ag-experienced T cells (20, 34; Fig.
7). A population of Tc 18–271 CD8 cells with similar phe-
notype and functional ability is present in patients resolv-
ing acute HBV infection (25).
These data show that there is a functional similarity be-
tween the core tetramer1 cells found in chronically in-
fected patients with low viremia and those found in pa-
tients controlling acute HBV infection.
Discussion
Although several reports have demonstrated that HBV
control does not require massive destruction of infected
hepatocytes (18, 35), inhibition of HBV replication in hu-
mans has always been linked to immune-mediated events
leading to liver inflammation. Thus, subjects with persis-
tent HBV infection but without signs of liver damage have
generally been considered to lack an active cellular re-
sponse to HBV (36, 37). We demonstrate the presence of
functionally active HBV-specific CD8 cells in the large
majority of chronic HBV-infected patients lacking evi-
dence of liver damage but controlling HBV replication.
Furthermore, HBV-specific CD8 cells are not only present
in the circulation but are within the liver in this group of
patients, demonstrating that peripheral tolerance and T cell
exhaustion of HBV-specific CD8 cells do not occur in this
patient population.
Figure 5. Ability of Tc 18–271
CD8 cells to expand after specific
peptide stimulation. PBMCs of the
indicated patients were stained with
Tc 18–27 and anti-CD8 mAbs be-
fore or after stimulation with core
18–27 peptide. Stimulated PBMCs
were cultured for 10 d and then ana-
lyzed by flow cytometry for the pres-
ence of Tc 18–271 cells (as shown in
the dot plots). The numbers of Tc
18–271 out of 5 3 104 cells were
calculated directly (white bars) or af-
ter 10 d stimulation (hatched bars) by
counting Tc 18–271CD81 cells out
of CD8 cells within the live gate.
The difference in expansion poten-
tial was significantly different be-
tween the two groups (P 5 0.004,
Fisher’s exact test).1277 Maini et al.
HCV-specific CTLs are also present in the normal liver
of chimpanzees 1 yr after resolution of acute HCV infection
(38). Furthermore, our findings have parallels with a murine
model of influenza virus infection in which efficient virus
control is strictly dependent on the kinetics and distribution
of the virus-specific CD8 response, but is not associated
with pathological damage induced by the immune response
(39, 40). The pattern of the HBV-specific CD8 response is
also similar to that seen in other human persistent virus in-
fections, such as EBV (33) and HTLV-I (41, 42), in which a
powerful CTL response can play an important role in limit-
ing virus replication without causing inflammatory disease.
Our data do not establish whether HBV-specific CD8
cells can control virus replication through the secretion of
cytokines alone or whether direct lysis of infected cells is
also involved. The sparsely scattered pattern of CD81 cells
within the liver parenchyma of patients with low level viral
replication suggests that secreted cytokines may be playing
a major role in antiviral control. The recent demonstration
of the efficacy of IFN-g in activating a pathway of intracel-
lular virus inactivation in the hepatocytes reinforces this in-
terpretation (35, 43). However, some degree of direct
hepatocyte lysis caused by HBV-specific CD8 cells may ex-
ist, which is not detectable by serum liver enzyme mea-
surement.
Patients with evidence of liver inflammation and a high
level of HBV replication show a different pattern of distri-
bution of HBV-specific CD8 cells. The frequency of these
cells is not above the background level in the circulation of
the great majority of the subjects tested. However, HBV-
specific CD8 cells are not completely deleted, as they are
detectable in the liver compartment. Although HLA–pep-
tide tetramers have the advantage of allowing direct and re-
producible quantification of HBV-specific CD8 cells (25),
they also have potential limitations. The detection of virus-
specific CD8 cells is dependent on the expression of TCRs
on their cell surface. Therefore, one interpretation of the
absence of tetramer-binding cells could be TCR downreg-
Figure 6. Functional characterization of circulating Tc 18–271 CD8 cells. (a) Cytolytic activity and IFN-g production of expanded Tc 18–271 CD8
cells. Tc 18–271 CD8 cells obtained after PBMC stimulation with core 18–27 peptide were tested for their ability to lyse HLA-A21 target cells pulsed or
unpulsed with 1 mM of core 18–27 peptide and to produce IFN-g after stimulation with PMA and ionomycin for 4 h. Experiments with lines derived
from patients 10, 7, and 14 are shown. For intracellular IFN-g production, staining with an IgG isotype control allowed the threshold for IFN-g–pro-
ducing cells to be determined. (b) IFN-g production of circulating Tc 18–271 CD8 cells. Circulating core 18–27-specific CD8 cells (from patient 10)
were tested for their ability to produce IFN-g after specific peptide stimulation. PBMCs were incubated with or without core 18–27 peptide (1 mm) for
6 h with addition of Brefeldin A (able to block release of intracellular cytokines) after the first 1 h. Cells were stained with Tc 18–27, anti-CD8, and anti–
IFN-g or isotype-matched IgG. The number of Tc 18–271 CD8 cells producing IFN-g with or without specific stimulation was calculated gating on
resting and activated lymphocytes by forward and side scatter, CD81 and Tc 18–271 cells.
Figure 7. Phenotypic analysis of Tc 18–271 CD8
cells. Fresh PBMCs from patients 10 and 7 were ana-
lyzed by three-color flow cytometry using the PE-con-
jugated Tc 18–27, Cychrome–conjugated anti-CD8,
and the following FITC-conjugated mAbs: anti–HLA-
DR, anti-CD38, anti-CD62L, and anti-CD45RA.
Dot plots show data after gating on CD81 T cells.1278 Role of HBV-specific CD8 Cells during Persistent Infection
ulation in the presence of high levels of Ag (21). However,
the fact that we can detect HBV-specific CD8 cells in the
liver, the site of maximal HBV replication, implies that
TCR downregulation does not completely abrogate their
detection, and that the absence of these cells in the periph-
ery is due to a genuine compartmentalization.
Another limitation of the tetramer technology is that it
can only be applied to the study of defined epitopes, and
cannot quantify the entire spectrum of CD81 cells specific
for HBV. We therefore cannot rule out the possibility that
HBV-specific CD8 responses in chronic patients could be
directed against epitopes other than those covered by the
HBV tetramers used in this study. However, these tetramers
have been synthesized because they cover the most frequent
CTL epitopes found in acutely and chronically infected pa-
tients after screening with multiple peptides (6–9). Further-
more, CD8 cells specific for core 18–27 appear to be nu-
merically dominant in the immunoprotective response
associated with the control of acute infection (25).
In the context of this dominant CD8 response, we found
that frequencies of intrahepatic Tc 18–271 CD8 cells are
lower in the majority of patients with high virus load than
in patients controlling the virus. However, the total number
of intrahepatic Tc 18–271 CD8 cells is likely to be of the
same magnitude in the two groups, because the higher CD8
infiltration in the group of patients with liver inflammation
could compensate for the lower frequency of tetramer-spe-
cific CD8 cells. If the quantity of core 18–27-specific cells is
not the variable determining the liver pathology, hepatocyte
damage may not be primarily due to lysis by HLA class
I–restricted HBV-specific CD8 cells, but might be the con-
sequence of the large infiltrate of T cells. It is tempting to
speculate that this infiltration may be largely nonvirus spe-
cific (44). Such recruitment of nonantigen-specific CD8
cells mediated by IFN-g has been demonstrated in a trans-
genic mouse model of fulminant hepatitis (45) and in the
setting of poor viral control in a mouse model of influenza
infection (39).
Support for the concept that the CD8 liver infiltrate may
have a large nonvirus-specific component comes from
several studies. In chronic hepatitis C, the frequency of
liver-infiltrating HCV-specific CD8 cells is very low (46),
suggesting that the bulk of intrahepatic CD8 cells are
nonantigen specific. In a transgenic mouse model of ful-
minant hepatitis, liver damage is only seen when infiltra-
tion of nonantigen-specific CD8 cells follows the Ag-spe-
cific component (45). Furthermore, in recent results from
chimpanzees infected with HBV, liver damage occurs con-
comitant with massive infiltration of CD8 cells (18). This
sequestration occurs after clearance of most of the HBV,
and is therefore unlikely to be composed primarily of
HBV-specific CD8 cells.
The data also show that viral replication does not depend
on the quantity of Tc 18–271 CD8 cells. We found that
completely different levels of HBV replication can coexist
with slightly different numbers in the circulation and with
comparable numbers of intrahepatic HBV-specific CD8
cells. Escape of CTL recognition due to mutations within
the epitope is not the explanation of this finding. The pres-
ence of similar numbers of virus-specific CD8 cells despite
large differences in viral load seems counterintuitive if CTLs
have an important role in viral control. However, this co-
nundrum has also been observed in HTLV-1 (41, 47) and
fits a mathematical model where steady-state CTL numbers
do not correlate with virus load (30). This model suggests
instead that the primary factor controlling viral load is CTL
responsiveness, which denotes the rate at which virus-spe-
cific CD8 cells expand and exert antiviral activity. Since ef-
ficient CTL responsiveness will result in a lowering of the
viral load, virus-specific CD8 numbers would fall with the
lower antigenic stimulus. Thus, at equilibrium, there may
be little discernible difference in actual CTL abundance be-
tween patients with high and low levels of HBV replication.
Our data from the two groups of HBV patients are con-
sistent with this model in that the most striking difference
between them is their CTL responsiveness rather than ac-
tual numbers at equilibrium. Patients controlling the virus
demonstrate circulating HBV-specific CD8 cells expressing
the phenotype of Ag-experienced resting cells. These cells
exhibit efficient proliferation after reencounter with the vi-
ral Ag, and can exert antiviral effector functions after such
expansion, demonstrating that patients without liver in-
flammation and with low viral load are characterized by the
potential to rapidly mount strong CD8 effector mecha-
nisms. This reservoir of circulating HBV-specific CD8 cells
able to expand after recognition of the specific virus se-
quence is not detectable in patients unable to control the
virus. This prevents phenotypic and functional comparison
of equivalent populations of HBV-specific CD8 between
the two groups, which might reveal possible mechanisms
contributing to chronicity. Whether these different out-
comes of chronic infection result from differences in the ef-
ficiency, kinetics (48), and distribution (40) of the antiviral
CD8 response, differences in CD4 T cell help (49), or dif-
ferences in the size or fitness of the initial virus inoculum
(21, 39) remains to be determined. However, recent studies
(Boni, C., manuscript in preparation) in HBeAg1 chronic
patients undergoing lamivudine treatment have shown that
a reduction in viral load allows repopulation with function-
ally active HBV-specific CD8 cells. This reconstitution of a
circulating reservoir of HBV-specific CTLs, combined
with the absence of hepatic inflammation mediated by
these cells when viral load is low, supports an immunother-
apeutic approach designed to boost HBV-specific CD8 re-
sponses.
In conclusion, measurement of circulating and intrahe-
patic HBV-specific CD8 cells in patients with differing vi-
ral load and liver pathology has provided new insights into
the pathogenesis of HBV infection. Our data show an ac-
tive HBV-specific CD8 response in patients controlling
HBV replication. The presence of liver-infiltrating HBV-
specific CD8 cells in the absence of liver inflammation sug-
gests that control of HBV replication and liver damage may
be independent events in these patients. Since comparable
quantities of core 18–27-specific CD8 cells are demonstra-
ble in the liver with a variable extent of damage, it is plau-1279 Maini et al.
sible that hepatocyte lysis might be the consequence of the
dense infiltrate of nonantigen-specific T cells.
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